Please assess the completion status of the following clinical trial:

Trial Title: Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Schizotypal Personality Disorder~Exclusion Criteria:~Over 65

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: EXPERIMENTAL): starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo match in identical tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).